Bergeson & Campbell, P.C. Contributes Chapter to Biointeractions of Nanomaterials
Bergeson & Campbell, P.C., (B&C®) is pleased to announce that Managing Partner Lynn L. Bergeson and the late Michael F. Cole prepared a chapter in a new book, Biointeractions of Nanomaterials, which covers a wide range of issues associated with the safety of nanomaterials in biological systems. The book, published on July 29, 2014, by CRC Press, addresses issues related to the toxicity and safety of nanomaterials and nanosystems, and covers a range of interactions in biological systems, specifically focusing on the tools and methods used for evaluation, including in vivo and in vitro techniques.
Ms. Bergeson and Mr. Cole’s chapter, The Regulatory Implications of Nanotechnology, examines the effect regulation is having or may have on the commercialization of nanomaterials in the pharmaceutical and medical fields in the U.S. and abroad. The chapter discusses the types of regulatory schemes being enacted or considered, and whether different governance systems are likely to have differing effects on nanomedicine, including the effect on competition among companies and countries.
More information is available online.
Lynn L. Bergeson is an internationally renowned expert on issues of governance, regulation, and policy regarding nanotechnology, biotechnology, and other emerging transformative technologies. Ms. Bergeson is on the NanoBusiness Advisory Board, is an Associate Editor of Nanotechnology Law & Business Journal, and writes frequently on nanotechnology issues, most recently in the article Nanomaterials and Public Disclosure: Are European Nano Product Registries the Answer? in the Summer 2014 issue of Natural Resources & Environment, the magazine of the American Bar Association (ABA) Section of Environment, Energy, and Resources (SEER); she is Vice Chair of the ABA SEER Committee on Pesticides, Chemical Regulation, and Right-to-Know. The late Michael F. Cole, formerly Of Counsel with B&C, was an attorney with encyclopedic understanding of the U.S. Food and Drug Administration (FDA) and impeccable educational and professional credentials. This chapter was one of Mr. Cole’s last works of scholarship before his passing in May 2014.